New Delhi: Biopharmaceutical company Biocon Ltd on Monday said it has received approval from the US Food and Drug Administration (FDA) for Pebrilzo (pertuzumab-qcay) injection, a biosimilar to Perjeta, used in the treatment of HER2-positive breast cancer.
Pebrilzo is a monoclonal antibody that treats HER2-positive breast cancer by blocking HER2 receptors on cancer cells. With this approval, Biocon now has five oncology biosimilar therapies approved in the United States, the company said in a regulatory filing.